Dario Carlo Altieri, an Italian-born physician-scientist, is the president and CEO of The Wistar Institute[1] in Philadelphia.
He trained in internal medicine with a postgraduate specialty degree in clinical and experimental hematology.
[1][4] His research has focused on Inhibitors of Apoptosis (IAP), a family of genes essential for proliferation and survival of cells.
[5][6][7] Altieri has also been involved in the development of gamitrinib, a Hsp90 inhibitor that was shown to disable the activity of mitochondria in cancerous cells.
In 2013, Altieri and his team received a $1.5 million grant from the United States Department of Defense to prepare the drug for human trials.